{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:13:09Z","timestamp":1790727189569,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Chinese National Science & Technology","award":["2008ZXJ09006001"],"award-info":[{"award-number":["2008ZXJ09006001"]}]},{"name":"Chinese National Science & Technology","award":["2015ZX09J15104"],"award-info":[{"award-number":["2015ZX09J15104"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.bcp.2016.09.012","type":"journal-article","created":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T11:16:11Z","timestamp":1474542971000},"page":"67-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib \u2013 Enhancement by ketoconazole"],"prefix":"10.1016","volume":"121","author":[{"given":"XiaoMei","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TianHong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SiJia","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunXia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinJing","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiYing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MingShe","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2016.09.012_b0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.lungcan.2010.11.007","article-title":"Phase I study of icotinib hydrochloride (BPI- 2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors","volume":"73","author":"Zhao","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2016.09.012_b0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.lungcan.2011.10.023","article-title":"Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies","volume":"76","author":"Tan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2016.09.012_b0015","first-page":"19","article-title":"Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer","volume":"124","author":"Ren","year":"2011","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.bcp.2016.09.012_b0020","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomized, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2016.09.012_b0025","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1517\/17425255.2015.1034688","article-title":"Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors\/inducers using physiologically based pharmacokinetic modeling","volume":"11","author":"Chen","year":"2015","journal-title":"Exp. Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcp.2016.09.012_b0030","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-07-0088","article-title":"Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes","volume":"13","author":"Li","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2016.09.012_b0035","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1124\/dmd.105.006205","article-title":"Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino) carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin from irinotecan","volume":"33","author":"Fujita","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0040","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1124\/dmd.110.037853","article-title":"Sorafenib and Sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1-hydroxylation","volume":"39","author":"Sugiyama","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0045","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1124\/dmd.31.9.1108","article-title":"Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine","volume":"31","author":"Galetin","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0050","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev.pharmtox.45.120403.100004","article-title":"Non-michaelis-menten kinetics in cytochrome P450-catalyzed reactions","volume":"45","author":"Atkins","year":"2005","journal-title":"Ann. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2016.09.012_b0055","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/j.1552-4604.1996.tb04251.x","article-title":"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents","volume":"36","author":"von Moltke","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2016.09.012_b0060","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1124\/dmd.30.8.883","article-title":"Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7","volume":"30","author":"Williams","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0065","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/dmd.31.7.938","article-title":"In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5","volume":"31","author":"Patki","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/dmd.108.024679","article-title":"Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5","volume":"37","author":"Okada","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0075","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1124\/dmd.114.057000","article-title":"Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide)","volume":"42","author":"Tseng","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0080","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.lungcan.2015.05.024","article-title":"Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer","volume":"89","author":"Liu","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2016.09.012_b0085","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1517\/14656566.2014.890183","article-title":"Icotinib: activity and clinical application in Chinese patients with lung cancer","volume":"15","author":"Guan","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bcp.2016.09.012_b0090","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1021\/bi00187a009","article-title":"Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site","volume":"33","author":"Shou","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2016.09.012_b0095","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1074\/jbc.M008799200","article-title":"A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4","volume":"276","author":"Shou","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2016.09.012_b0100","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1124\/dmd.30.12.1512","article-title":"Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach","volume":"30","author":"Galetin","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0105","first-page":"67","article-title":"Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids","volume":"41","author":"Buening","year":"1981","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2016.09.012_b0110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/aps.2010.218","article-title":"Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib","volume":"32","author":"Dong","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2016.09.012_b0115","series-title":"Cytochrome P450: Structure, Mechanism, and Biochemistry","first-page":"377","article-title":"Human cytochrome P450 enzymes","author":"Guengerich","year":"2005"},{"key":"10.1016\/j.bcp.2016.09.012_b0120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/138920008783331121","article-title":"Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5","volume":"9","author":"Niwa","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bcp.2016.09.012_b0125","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2217\/pgs.13.133","article-title":"Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism","volume":"14","author":"de Jungle","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bcp.2016.09.012_b0130","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.TP.0000090753.99170.89","article-title":"Impact of cytochrome P4503A5 genetic polymorphism on tacrolimus doses and concentration-to dose ratio in renal transplant recipients","volume":"76","author":"Thervet","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.bcp.2016.09.012_b0135","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.13788","article-title":"Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype","author":"Pallet","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.bcp.2016.09.012_b0140","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2016.09.012_b0145","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1124\/dmd.30.10.1108","article-title":"Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA","volume":"30","author":"Koch","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0150","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2016.09.012_b0155","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2133\/dmpk.19.120","article-title":"CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects","volume":"19","author":"Yamaori","year":"2004","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2016.09.012_b0160","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1124\/dmd.111.043844","article-title":"Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 19-hydroxylation in vitro","volume":"40","author":"Keubler","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0165","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1124\/dmd.115.064006","article-title":"A screen of approved drugs identifies the androgen receptor antagonist flutamide and its pharmacologically active metabolite 2-hydroxy-flutamide as heterotropic activators of cytochrome P450 3A in vitro and in vivo","volume":"43","author":"Blobaum","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0170","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1124\/dmd.113.052662","article-title":"Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions","volume":"41","author":"Blobaum","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1124\/mol.110.064246","article-title":"Deletion of microsomal cytochrome b5 profoundly affects hepatic and extrahepatic drug metabolism","volume":"78","author":"McLaughlin","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2016.09.012_b0180","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/dmd.115.068569","article-title":"The role of protein-protein and protein-membrane interactions on P450 function","volume":"44","author":"Scott","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0185","doi-asserted-by":"crossref","first-page":"27438","DOI":"10.1074\/jbc.271.44.27438","article-title":"Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4\/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5","volume":"271","author":"Yamazaki","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2016.09.012_b0190","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.bcp.2003.08.004","article-title":"Effects of cytochrome b5 on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7","volume":"66","author":"Yamaori","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2016.09.012_b0195","first-page":"1150","article-title":"Mechanism of cytochrome P450 activation by caffeine and 7,8-benzoflavone in rat liver microsomes","volume":"25","author":"Lee","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0200","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1124\/dmd.107.014910","article-title":"CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis","volume":"35","author":"Locuson","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.09.012_b0205","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/clpt.2011.178","article-title":"Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam","volume":"91","author":"Yang","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2016.09.012_b0210","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0022-3565(24)35211-5","article-title":"Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism","volume":"291","author":"Tang","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2016.09.012_b0215","doi-asserted-by":"crossref","first-page":"13682","DOI":"10.1073\/pnas.0603236103","article-title":"Structural basis for ligand promiscuity in cytochrome P450 3A4","volume":"103","author":"Ekroos","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2016.09.012_b0220","doi-asserted-by":"crossref","first-page":"17672","DOI":"10.1016\/S0021-9258(19)77889-2","article-title":"Positive effectors of the binding of an active site-directed amino steroid to rabbit cytochrome P-4503c","volume":"263","author":"Johnson","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2016.09.012_b0225","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.2042-7158.2010.01202.x","article-title":"Mechanism of cytochrome P450\u20133A inhibition by ketoconazole","volume":"63","author":"Greenblatt","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bcp.2016.09.012_b0230","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.3390\/molecules20057558","article-title":"Pi-pi stacking mediated cooperative mechanism for human cytochrome P450 3A4","volume":"20","author":"Fa","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2016.09.012_b0235","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0006-2952(94)90543-6","article-title":"Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily","volume":"47","author":"Gorski","year":"1994","journal-title":"Biochem. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216302957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216302957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T20:41:07Z","timestamp":1749588067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295216302957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":47,"alternative-id":["S0006295216302957"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2016.09.012","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib \u2013 Enhancement by ketoconazole","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2016.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}